FDA Red Flags Drugs Due to Safety Issues

How can you keep pace with an accelerating marketing ecosystem? Join us at Brandweek Sept. 12–16 in Miami alongside leading CMOs, founders and change makers from GatoradeMarriottAlo YogaCampbell'sUncommon James and more. Book now.

Duloxetine (Cymbalta), Insulin U-500 (Humulin R), Nitroglycerin (Nitrostat) and Natalizumab (Tysabri) were among 20 drugs flagged this week by the U.S. Food and Drug Administration in a report that lists drugs “being evaluated for potential safety issues.” The drugs have been identified based on a review of reports in FDA’s Adverse Event Reporting System.

AW+

WORK SMARTER - LEARN, GROW AND BE INSPIRED.

Subscribe today!

To Read the Full Story Become an Adweek+ Subscriber

View Subscription Options

Already a member? Sign in